743340
Last Update Posted: 2018-04-26
Recruiting has ended
All Genders accepted | 1 months-17 Years |
50 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.
Eligibility
Relevant conditions:
HIV-1 Infection
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov